The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities

Clinical Infectious Diseases

Volumn 38, Issue 5, 2004, Pages 743-753

  Anderson, Peter L ^a,c   Kakuda, Thomas N ^b   Lichtenstein, Kenneth A ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALPHA INTERFERON; CARBOVIR; CYTOKINE; DIDANOSINE; EMTRICITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; LAMIVUDINE; NUCLEOSIDE; PHYTOHEMAGGLUTININ; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; ZALCITABINE; ZIDOVUDINE; ANTIVIRUS AGENT; RNA DIRECTED DNA POLYMERASE;

ANTIVIRAL ACTIVITY; CELL ACTIVATION; DRUG BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDEMIA; LIPODYSTROPHY; MITOCHONDRIAL TOXICITY; PANCREATITIS; PERIPHERAL NEUROPATHY; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEX DIFFERENCE; TOXICITY; BLOOD; DRUG ANTAGONISM; FEMALE; MALE; METABOLISM;

ANTIVIRAL AGENTS; FEMALE; HIV INFECTIONS; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; NUCLEOSIDES; PHOSPHORYLATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 1442351728     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/381678     Document Type: Review

References (130)

1. US Public Health Service. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov/guidelines/default_db2.asp?id=50. Accessed 12 January 2004.
2. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society - USA Panel. JAMA 2002; 288:222-35.
3. Powderly WG. Long-term exposure to lifelong therapies. J Acquir Immune Defic Syndr 2002; 29(Suppl 1):S28-40.
4. Brinkman K, Kakuda TN. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Curr Opin Infect Dis 2000; 13:5-11.
5. Lenert LA, Feddersen M, Sturley A, Lee D. Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection. Am J Med 2002; 113:229-32.
6. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 2000; 22:911-36; discussion 898.
7. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354:1112-5.
8. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-30.
9. Dalakas MC. Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst 2001; 6:14-20.
10. Chen D, Misra A, Garg A. Lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 2002; 87:4845-56.
11. Dieterich DT. Long-term complications of nucleoside reverse transcriptase inhibitor therapy. AIDS Read 2003; 13:176-84, 187.
12. Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard BG. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 2002; 16:1341-9.
13. Boxwell DE, Styrt BA. Lactic acidosis (LA) in patients receiving nucleoside reverse transcriptors (NRTIs) [abstract 1284]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999:496.
14. John M, Mallal S. Hyperlactatemia syndromes in people with HIV infection. Curr Opin Infect Dis 2002; 15:23-9.
15. Fortgang IS, Belitsos PC, Chaisson RE, Moore RD. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog anti-retroviral therapy. Am J Gastroenterol 1995; 90:1433-6.
16. Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis 2001; 33:1914-21.
17. 2-RIBAVIC Study) [abstract 1735]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
18. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357:280-1.
19. Sauleda S, Juarez A, Esteban JI, et al. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology 2001; 34:1035-40.
20. Harris M, Tesiorowski A, Chan K, et al. Lactic acidosis complicating antiretroviral therapy: frequency and correlates [abstract 34]. Antivir Ther 2000; 5:31.
21. Bonnet F, Bonarek M, Abridj A, et al. Severe lactic acidosis in HIV-infected patients treated with nucleosidic reverse transcriptase analogs: a report of 9 cases [in French]. Rev Med Interne 2003; 24:11-6.
22. Bonnet F, Bonarek M, Morlat P, et al. Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control study. Clin Infect Dis 2003; 36:1324-8.
23. Kovacs JA, Bechtel C, Davey RT Jr, et al. Combination therapy with didanosine and interferon-α in human immunodeficiency virus-infected patients: results of a phase I/II trial. J Infect Dis 1996; 173:840-8.
24. Moore RD, Wong WM, Keruly JC, McArthur JC. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS 2000; 14:273-8.
25. Chen X, Goudsmit J, van der Kuyl AC. Lack of correlation between length variation in the DNA polymerase γ gene CAG repeat and lactic acidosis or neuropathy during antiretroviral treatment. AIDS Res Hum Retroviruses 2002; 18:531-4.
26. Fischl MA, Richman DD, Saag M, et al. Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-α2a in patients with HIV. AIDS Clinical Trials Group Study 197. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:247-53.
27. Galli M, Ridolfo AL, Adorni F, et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002; 29:21-31.
28. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357:592-8.
29. Currier J, Carpenter C, Daar E, Kotler D, Wanke C. Identifying and managing morphologic complications of HIV and HAART. AIDS Read 2002; 12:114-9, 124-5.
30. Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003; 32:48-56.
31. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14:1309-16.
32. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001; 15:1389-98.
33. Chene G, Angelini E, Cotte L, et al. Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis 2002; 34:649-57.
34. Cossarizza A, Mussini C, Vigano A. Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders? Bioessays 2001; 23:1070-80.
35. Boufassa F, Dulioust A, Lascaux AS, et al. Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response. HIV Clin Trials 2001; 2:339-45.
36. Wurtz R, Ceaser S. Adipose redistribution in human immunodeficiency virus-seropositive patients: association with CD4 response. Clin Infect Dis 2000; 31:1497-8.
37. Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001; 15:231-9.
38. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clin Infect Dis 2000; 31:1482-7.
39. Mauss S, Corzillius M, Wolf E, et al. Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Med 2002; 3:49-55.
40. John M, Nolan D, Mallal S. Antiretroviral therapy and the lipodystrophy syndrome. Antivir Ther 2001; 6:9-20.
41. Rakotoambinina B, Medioni J, Rabian C, Jubault V, Jais JP, Viard JP. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J Acquir Immune Defic Syndr 2001; 27:443-9.
42. Zylberberg H, Nalpas B, Pol S, Brechot C, Viard JP. Is there a relationship between hepatitis C virus infection and antiretroviral-associated lipoatrophy? AIDS 2000; 14:2055.
43. Stretcher BN, Pesce AJ, Frame PT, Stein DS. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994; 38:1541-7.
44. Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 2003; 17:2159-68.
45. Hoggard PG, Back DJ. Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules. Curr Opin Infect Dis 2002; 15:3-8.
46. Stein DS, Moore KH. Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians. Pharmacotherapy 2001; 21:11-34.
47. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22:685-708.
48. Van Rompay AR, Johansson M, Karlsson A. Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. Pharmacol Ther 2000; 87:189-98.
49. Dalakas MC, Semino-Mora C, Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′,3′-dideoxycytidine (ddC). Lab Invest 2001; 81:1537-44.
50. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990; 322:1098-105.
51. Shikuma CM, Hu N, Milne C, et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001; 15:1801-9.
52. Johnson AA, Ray AS, Hanes J, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001; 276:40847-57.
53. Martin JL, Brown CE, Matthews-Davis N, Reardon JE. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994; 38:2743-9.
54. Lewis W, Copeland WC, Day BJ. Mitochondrial DNA depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. Lab Invest 2001; 81:777-90.
55. Robbins BL, Wilcox CK, Fridland A, Rodman J. Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacotherapy 2003; 23:695-701.
56. Perno CF, Cooney DA, Gao WY, et al. Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages. Blood 1992; 80:995-1003.
57. Gao WY, Shirasaka T, Johns DG, Broder S, Mitsuya H. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993; 91:2326-33.
58. Gao WY, Agbaria R, Driscoll JS, Mitsuya H. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 1994; 269:12633-8.
59. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 1998; 42:612-7.
60. Soler C, Garcia-Manteiga J, Valdes R, et al. Macrophages require different nucleoside transport systems for proliferation and activation. FASEB J 2001; 15:1979-88.
61. Hoggard PG, Kewn S, Maherbe A, et al. Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea. AIDS 2002; 16:2439-46.
62. Kewn S, Hoggard PG, Sales SD, Johnson MA, Back DJ. The intracellular activation of lamivudine (3TC) and determination of 2′-deoxycytidine- 5′-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells. Br J Clin Pharmacol 2000; 50:597-604.
63. Dolce V, Fiermonte G, Runswick MJ, Palmieri F, Walker JE. The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals. Proc Natl Acad Sci U S A 2001; 98:2284-8.
64. Sales SD, Hoggard PG, Sunderland D, Khoo S, Hart CA, Back DJ. Zidovudine phosphorylation and mitochondrial toxicity in vitro. Toxicol Appl Pharmacol 2001; 177:54-8.
65. Stretcher BN, Pesce AJ, Frame PT, Greenberg KA, Stein DS. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity. AIDS 1994; 8:763-9.
66. Harris M, Back D, Kewn S, Jutha S, Marina R, Montaner JS. Intracellular carbovir triphosphate levels in patients taking abacavir once a day. AIDS 2002; 16:1196-7.
67. Kewn S, Hoggard PG, Sales SD, et al. Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2002; 46:135-43.
68. Becher F, Landman R, Mboup S, et al. Monitoring of didanosine and stavudine intracellular triphosphorylated anabolite concentrations in HIV-infect patients. AIDS 2004; 18:181-7.
69. Rousseau FS, Kahn JO, Thompson M, et al. Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). J Antimicrob Chemother 2001; 48:507-13.
70. Rodriguez JF, Rodriguez JL, Santana J, Garcia H, Rosario O. Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals. Antimicrob Agents Chemother 2000; 44:3097-100.
71. Salmon-Ceron D, Lassalle R, Pruvost A, et al. Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and hepatitis C virus: a CORIST-ANRS HC1 trial. Clin Infect Dis 2003; 36:1295-304.
72. Pruvost A, Theodoro F, Hascoet S, et al. Development and validation of a direct LC/MS/MS assay for intracellular tenofovir-diphosphate in human PBMCs [abstract 837]. Antivir Ther 2003; 8(Suppl 1):S420.
73. Traut TW. Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 1994; 140:1-22.
74. Broder S. Pharmacodynamics of 2′,3′-dideoxycytidine: an inhibitor of human immunodeficiency virus. Am J Med 1990; 88:2S-7S.
75. Yarchoan R, Pluda JM, Thomas RV, et al. Long-term toxicity/activity profile of 2′,3′-dideoxyinosine in AIDS or AIDS-related complex. Lancet 1990; 336:526-9.
76. Fischl MA, Parker CB, Pettinelli C, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med 1990; 323:1009-14.
77. Skowron G. Biologic effects and safety of stavudine: overview of phase I and II clinical trials. J Infect Dis 1995; 171(Suppl 2):S113-7.
78. Browne MJ, Mayer KH, Chafee SB, et al. 2′,3′-Didehydro- 3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis 1993; 167:21-9.
79. Moyle G. Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism? Drug Saf 2000; 23:467-81.
80. + responses to nucleoside analogue therapy for HIV infection. The AIDS Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr 2000; 24:316-24.
81. Sloan JA, Goldberg RM, Sargent DJ, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 2002; 20:1491-8.
82. Grem JL. Cancer chemotherapy principles and practice. Philadelphia: JB Lippincott, 1990.
83. Barry MG, Khoo SH, Veal GJ, et al. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS 1996; 10:1361-7.
84. Hoggard PG, Lloyd J, Khoo SH, et al. Zidovudine phosphorylation determined sequentially over 12 months in human immunodeficiency virus-infected patients with or without previous exposure to antiretroviral agents. Antimicrob Agents Chemother 2001; 45:976-80.
85. Barry M, Wild M, Veal G, et al. Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS 1994; 8:F1-5.
86. Rodman JH, Robbins B, Flynn PM, Fridland A. A systemic and cellular model for zidovudine plasma concentrations and intracellular phosphorylation in patients. J Infect Dis 1996; 174:490-9.
87. Anderson PL, Brundage RC, Weller D, Kawle SP, Bushman L, Fletcher CV. The pharmacokinetics of zidovudine-triphosphate (ZDV-TP) in HIV-infected adults [abstract 6.3]. In: Program and abstracts of the 3rd International Workshop on Clinical Pharmacology of HIV Therapy (Washington, DC). Utrecht, The Netherlands: Virology Education, 2002:6.3.
88. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987; 317:192-7.
89. Hestdal K, Aukrust P, Muller F, et al. Dysregulation of membrane-bound tumor necrosis factor-α and tumor necrosis factor receptors on mononuclear cells in human immunodeficiency virus type 1 infection: low percentage of p75-tumor necrosis factor receptor positive cells in patients with advanced disease and high viral load. Blood 1997; 90:2670-9.
90. Godfried MH, van der Poll T, Jansen J, et al. Soluble receptors for tumour necrosis factor: a putative marker of disease progression in HIV infection. AIDS 1993; 7:33-6.
91. Finck BN, Johnson RW. Tumor necrosis factor-α regulates secretion of the adipocyte-derived cytokine, leptin. Microsc Res Tech 2000; 50:209-15.
92. Martin-Romero C, Santos-Alvarez J, Goberna R, Sanchez-Margalet V. Human leptin enhances activation and proliferation of human circulating T lymphocytes. Cell Immunol 2000; 199:15-24.
93. + T lymphocytes during HIV-1 infection. Clin Exp Immunol 1994; 95:436-41.
94. Behbahani H, Landay A, Patterson BK, et al. Normalization of immune activation in lymphoid tissue following highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 25:150-6.
95. Pluda JM, Yarchoan R, Smith PD, et al. Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection. Blood 1990; 76:463-72.
96. Scadden DT, Pickus O, Hammer SM, et al. Lack of in vivo effect of granulocyte-macrophage colony-stimulating factor on human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1996; 12:1151-9.
97. Corica F, Allegra A, Corsonello A, et al. Relationship between plasma leptin levels and the tumor necrosis factor-α system in obese subjects. Int J Obes Relat Metab Disord 1999; 23:355-60.
98. Pernerstorfer-Schoen H, Jilma B, Perschler A, et al. Sex differences in HAART-associated dyslipidaemia. AIDS 2001; 15:725-34.
99. Olsen NJ, Kovacs WJ. Gonadal steroids and immunity. Endocr Rev 1996; 17:369-84.
100. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000; 25:312-21.
101. Ledru E, Christeff N, Patey O, de Truchis P, Melchior JC, Gougeon ML. Alteration of tumor necrosis factor-α T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 2000; 95:3191-8.
102. Christeff N, Melchior JC, de Truchis P, Perronne C, Gougeon ML. Increased serum interferon alpha in HIV-1 associated lipodystrophy syndrome. Eur J Clin Invest 2002; 32:43-50.
103. Maher B, Alfirevic A, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M. TNF-α promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 2002; 16:2013-8.
104. Bastard JP, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359:1026-31.
105. Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105:804-9.
106. Hohler T, Kruger A, Gerken G, Schneider PM, Meyer zum Buschenefelde KH, Rittner C. A tumor necrosis factor-alpha (TNF-α) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 1998; 111:579-82.
107. Hohler T, Kruger A, Gerken G, Schneider PM, Meyer zum Buschenfelde KH, Rittner C. Tumor necrosis factor alpha promoter polymorphism at position - 238 is associated with chronic active hepatitis C infection. J Med Virol 1998; 54:173-7.
108. Balzarini J, Lee CK, Herdewijn P, De Clercq E. Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′- dideoxyinosine against human immunodeficiency virus. J Biol Chem 1991; 266:21509-14.
109. Kimball P, Elswick RK, Shiffman M. Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-α therapy. J Med Virol 2001; 65:510-6.
110. Fletcher CV, Acosta EP, Henry K, et al. Concentration-controlled zidovudine therapy. Clin Pharmacol Ther 1998; 64:331-8.
111. + lymphocytes and relationship to serum TNF-α, IFN-γ, and sIL-2R levels in aging. Exp Gerontol 1999; 34:79-93.
112. Fletcher CV, Kawle SP, Kakuda TN, et al. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS 2000; 14:2137-44.
113. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-8.
114. Jones S, Janneh O, Maher B, Khoo S, Back D, Pirmohamed M. Altered TNF-α and IL-6 levels and antiadipogenic effects of anti-retorivirals on cultured adipocytes: possible mechanisms for their role in lipodystrophy in HIV-infected patients. Antivir Ther 2002; 7:L2.
115. Hoggard PG, Manion V, Barry MG, Back DJ. Effect of protease inhibitors on nucleoside analogue phosphorylation in vitro. Br J Clin Pharmacol 1998; 45:164-7.
116. Lewis W, Haas CP, Raidel SM, et al. Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice. Lab Invest 2001; 81:1527-36.
117. Kleiner DE, Gaffey MJ, Sallie R, et al. Histopathologic changes associated with fialuridine hepatotoxicity. Mod Pathol 1997; 10:192-9.
118. McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FLAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333:1099-105.
119. Cherry CL, Wesselingh SL. Nucleoside analogues and HIV: the combined cost to mitochondria. J Antimicrob Chemother 2003; 51:1091-3.
120. Cherry CL, McArthur JC, Hoy JF, Wesselingh SL. Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol 2003; 26:195-207.
121. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346:811-20.
122. Pardo CA, McArthur JC, Griffin JW. HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. J Peripher Nerv Syst 2001; 6:21-7.
123. Kotler DP. HIV infection and lipodystrophy. Prog Cardiovasc Dis 2003; 45:269-84.
124. Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 2000; 68:437-46.
125. McGovern B, Bica I. Risk of HAART therapy in hepatitis C. Hepatology 2002; 35:730.
126. Hoggard PG, Veal GJ, Wild MJ, Barry MG, Back DJ. Drug interactions with zidovudine phosphorylation in vitro. Antimicrob Agents Chemother 1995; 39:1376-8.
127. Hoggard PG, Kewn S, Barry MG, Khoo SH, Back DJ. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997; 41:1231-6.
128. Brau N. Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions and therapy. AIDS 2003; 17:2279-90.
129. Becher F, Pruvost A, Goujard C, et al. Improved method for the simultaneous determination of d4T, 3TC and ddl intracellular phosphorylated anabolites in human peripheral-blood mononuclear cells using high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2002; 16:555-65.
130. Dabis F, Ekpini ER. HIV-1/AIDS and maternal and child health in Africa. Lancet 2002; 359:2097-104.